CHU d'Annecy
- Address
- 1 Avenue De L Hopital, Bp 90074, 74370 Epagny Metz Tessy, France
Neoplasms
At CHU d'Annecy the oncology department conducts extensive trials on solid tumours and haematologic malignancies, aiming to evaluate new therapies and improve survival.
- Advanced lung cancer
- Breast cancer subtypes
- Colorectal carcinoma
- Pancreatic adenocarcinoma
- Renal cell carcinoma
Over 130 trials involve 59 investigators, reflecting a strong focus on innovative cancer treatment.
Cardiovascular Diseases
Research targets heart failure, atherosclerotic disease and arrhythmia, testing novel drugs and preventive strategies to reduce mortality.
- Heart failure management
- Atherosclerotic cardiovascular disease
- Out‑of‑hospital cardiac arrest
- Hypertension control
- Anticoagulation in renal patients
Trials explore both pharmacologic and device‑based interventions to enhance cardiac outcomes.
Respiratory Tract Diseases
Studies focus on chronic obstructive pulmonary disease, severe asthma and emerging infections, evaluating biologics and antibiotics to improve lung function.
- Severe eosinophilic asthma
- COPD exacerbation prevention
- Mycobacterium xenopi pulmonary infection
- Ventilator‑associated pneumonia
- Respiratory syncytial virus
The site leverages its intensive care unit to assess acute and chronic respiratory conditions.
Immune System Diseases
Trials investigate autoimmune disorders and immune‑mediated hematologic conditions, testing targeted agents to modulate immune response.
- Systemic sclerosis
- Giant cell arteritis
- Eosinophilic granulomatosis with polyangiitis
- Waldenström macroglobulinemia
- Immune thrombocytopenia
Research includes biomarker‑driven approaches to personalize immunotherapy.
Bacterial Infections and Mycoses
Clinical studies address prosthetic joint infections, recurrent Clostridioides difficile and chronic hepatitis D, aiming to identify optimal antimicrobial regimens.
- Staphylococcal prosthetic joint infection
- Recurrent C. difficile infection
- Chronic hepatitis D
- Cutibacterium spp. infection
- Ventilator‑associated pneumonia
Safety and efficacy of novel antibiotics and de‑escalation strategies are central themes.
Digestive System Diseases
Research includes colorectal, biliary and gastric cancers as well as inflammatory bowel conditions, evaluating combination chemotherapies and targeted agents.
- Locally advanced rectal cancer
- Biliary tract carcinoma
- Gastric adenocarcinoma
- Small bowel adenocarcinoma
- Inflammatory bowel disease
Trials often integrate surgical outcomes with systemic therapy assessments.
Health Care Economics and Organizations
Studies assess cost‑effectiveness of new oncology drugs and health‑service delivery models to inform policy.
- Economic evaluation of immunotherapy
- Resource utilization in intensive care
- Patient‑reported outcome measures
- Value‑based pricing
- Health system pathways
Findings support evidence‑based decision‑making within the French health system.
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Investigations develop advanced imaging, liquid biopsy and digital monitoring tools to refine diagnosis and treatment monitoring.
- Circulating tumor DNA surveillance
- Advanced PET‑CT imaging
- Digital inhaler adherence tracking
- AI‑driven pathology analysis
- Remote patient monitoring
Integration of cutting‑edge technology enhances trial precision and patient safety.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 265 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 254 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 43 by active trials.
lock +42 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +25 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU d'Annecy
lock Showing 1 of 142 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 265 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 11 | Unknown | 2014-12-23 | 2026-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.